Prostate Cancer | Recent research and Discoveries | Oncotarget
Open-access, peer-reviewed research on Prostate Cancer from Oncotarget
Related Articles
Vinay Prasad named chief medical and science officer at FDA
Vinay Prasad is taking on several big roles at the FDA, solidifying his position as a top advisor to Commissioner Marty Makary.
Large B cell lymphoma microenvironment archetype profiles
Li et al. use single nucleus sequencing of 217 large B cell lymphomas to identify microenvironment archetype profiles (LymphoMAPs), discovering their divergent biology and association…
XPO1R749Q Mutations Co-occur with POLE Mutations in Cancer and can be Targeted to Overcome Chemoresistance – PubMed
XPO1 is a nuclear export receptor that is essential for cell survival. Previous genomic analyses have identified recurrent XPO1 hotspot mutations in cancer. Here, we…
An opportunity for Trump: Position U.S. cancer science to lead the world – The Cancer Letter
NIH budget from 1938-1960 NIH and NCI budgets from 1960-1993 Last November, the American public voted on America First causes, which include the greatest scientific…
Top Oncotarget Publications by Altmetric Score | Oncotarget
Oncotarget publications with an Altmetric Attention Score higher than 100
Iranian missile strike devastates two buildings at Israel’s Weizmann Institute
Hundreds of scientists have lost labs, equipment, and specimens
Senescence in cancer
Colucci et al. review the defining features of senescence in cancer, its roles in tumor cells, the stroma, and the immune system, and its context-dependent…
Vinay Prasad named chief medical and science officer at FDA
Vinay Prasad is taking on several big roles at the FDA, solidifying his position as a top advisor to Commissioner Marty Makary.
Aspirin ‘may be harmful’ to patients with colorectal cancer liver metastases
CHICAGO — Daily adjuvant aspirin did not reduce disease recurrence for patients with colorectal cancer liver metastases and may increase risk for death, according to…
Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment – PubMed
Heavily pretreated metastatic colorectal cancer (mCRC) poses significant therapeutic challenges. Advances in molecular profiling enables personalized strategies. We present a 62-year-old male with mCRC harboring…